企業プロフィール
Amylyx 株価・ニュース・カタリスト
- ティッカー:
- AMLX
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
28.08 USD (-3.51%)
終値
最終更新: 2026年10月1日
1.48B USD
時価総額
株価変動の要因
2026年10月1日 時点で AMLX は 3.51% 下落し、$28.08 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Neuroendocrine and Rare-Disease Biotechnology Company
Amylyx Pharmaceuticals develops therapies for endocrine and neurological diseases with limited treatment options. Its portfolio combines peptide therapeutics, antisense oligonucleotides, and small-molecule approaches across post-bariatric hypoglycemia, amyotrophic lateral sclerosis, Wolfram syndrome, and related disorders.
Avexitide and Post-Bariatric Hypoglycemia
Avexitide is a GLP-1 receptor antagonist designed to reduce the excessive insulin response that drives post-bariatric hypoglycemia. It is the company's lead late-stage asset and has received Breakthrough Therapy designation for both post-bariatric hypoglycemia and congenital hyperinsulinism.
Neurology Programs
AMX0114 is an antisense oligonucleotide targeting calpain-2 for amyotrophic lateral sclerosis. The program is in first-in-human development and reflects Amylyx's effort to build a mechanistically differentiated neurology pipeline beyond its earlier commercial history.
Wolfram Syndrome Development
AMX0035 is being studied in Wolfram syndrome, a rare genetic disorder affecting pancreatic beta cells, vision, and neurological function. Open-label clinical findings have supported continued discussions with the FDA regarding a potential Phase 3 study.
Next-Generation Endocrine Pipeline
AMX0318 is a long-acting GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia and other rare endocrine diseases. Amylyx is using external research collaborations to identify additional peptide candidates and broaden its endocrine portfolio.
今後のカタリスト
- Topline Phase 3 LUCIDITY data for avexitide in post-bariatric hypoglycemia in late August or early September 2026.
- Potential avexitide NDA submission and commercial launch in 2027, subject to positive data and regulatory review.
- IND filing for long-acting GLP-1 receptor antagonist AMX0318 in 2027.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。